Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fcvm.2018.00092 http://scihub22266oqcxt.onion/10.3389/fcvm.2018.00092 C6052659!6052659!30050909     free     free     free       Front+Cardiovasc+Med 2018 ; 5 (ä): ä Nephropedia Template TP {{tp|p=30050909|t=2018. Expanding TAVI to Low and Intermediate Risk Patients |pdf=|usr=}}{{30050909}} gab.com Text Expanding TAVI to Low and Intermediate Risk Patients JO: Front Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=30050909 #FOAvip TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges?particularly with regard to valve durability?need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines. Twit Text FOAVip Expanding TAVI to Low and Intermediate Risk Patients ????Front Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=30050909 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30050909 #FOAvip English Wikipedia <ref>{{Cite pmid|30050909}}</ref> Expanding TAVI to Low and Intermediate Risk Patients #MMPMID30050909 Voigtländer L; Seiffert M Front Cardiovasc Med 2018[]; 5 (ä): ä PMID30050909show ga TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges?particularly with regard to valve durability?need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines. äExpanding TAVI to Low and Intermediate Risk Patients (epmc).pdf DeepDyve Pubget Overpricing